Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Investor Presentation (February 2025)
36 slides from Pyc Therapeutics's investor presentation, Feb 17, 2025
Slide 1: Capital raising presentation
Life-changing science Capital raising presentation February 2025 Not for release to US wire services or distribution in the United States
Slide 2: Important Notices
Important Notices Important Information and Disclaimer You must read the following notices before reading or making any use of this document or any information contained in this document. By continuing to read, use or otherwise act on this document, you agree to be bound by the following terms and c
Slide 3: Important Notices: Joint Lead Manager disclaimer
Important Notices Joint Lead Manager (JLM) disclaimer E&P Capital Pty Ltd and Barrenjoey Markets Pty Limited (Joint Lead Managers) are acting as joint lead managers to the Entitlement Offer (as defined in this presentation). To the maximum extent permitted by law, the Joint Lead Managers and their r
Slide 4: Important Notices: Forward-looking Statements
Important Notices Forward-looking Statements and aspirational targets Some statements in this Presentation regarding estimates or future events are forward-looking statements. They include indications of, and guidance on, future matters. Forward-looking statements include, but are not limited to, st
Slide 5: Important Notices: Industry data
Important Notices Industry data Certain market and industry data used in connection with this Presentation, including in relation to other companies in PYC’s peer group, may have been obtained from public filings, research, surveys or studies conducted by third parties, including industry or general
Slide 6: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) Any forward-looking statements in this presentation have been prepared on the basis of a number of [‘PYC’]. These slides have been prepared as a presentation aid only and the inf
Slide 7: Executive Summary
Executive Summary Company introduction PYC Therapeutics is a drug development company with 3 clinical-stage assets. Each of PYC’s drug development programs has the potential to become the standard of care in areas of high unmet patient need (markets worth $1-$10 billion per annum)1 Capital raising o
Slide 8: Highlights of PYC's pipeline – three clinical-stage assets
Highlights of PYC’s pipeline – three clinical-stage assets 1 2 3 4 5 Disease-modifying In areas of major With the highest Validated in patient- Generating human drug candidates unmet need probability of success derived models efficacy data in 2025 5x Each of PYC’s pipeline In a disease with no With
Slide 9: PYC has built a pipeline of drug candidates with the potential to become the standard of care
PYC has built a pipeline of drug candidates with the potential to become the standard of care in areas of major unmet need Historical progress Progress expected in 20251 Program Pre-clinical Clinical Prevalence2 VP-0013 Retinitis Pigmentosa Type 11 1 in 100,000 PYC-001 Autosomal Dominant Optic Atrop
Slide 10: PYC can extend its cash runway to >$200m through the Offer
PYC can extend its cash runway to >$200m through the Offer1 Successful completion of the Offer will see PYC fully funded to progress all four pipeline programs through to FY272 Program Indication Key milestone(s) to be delivered3 VP-001 RP11 • Safety and efficacy read-outs from an extended Phase 1/2
Slide 11: This funding extension will deliver human safety and efficacy data in four drug programs
This funding extension1 will deliver human safety and efficacy data in four drug programs with best-in-class potential2 Successful completion of the Offer will see PYC fully funded to progress all four pipeline programs through to FY271 Program 2025 2026 2027 20283 RP11 VP-001 Ph1/2 study Registrati
Slide 12: Parent of a patient with Retinitis Pigmentosa quote
“One of the hardest things I ever heard in my life was when we were in her appointment as she was being diagnosed, and she asked me, ‘Am I going to go blind?’” Parent of a patient with Retinitis Pigmentosa https://www.fightingblindness.org/stories/life-as-a-teen-with-retinitis-pigmentosa-138 PYC THE
Slide 13: Clinical efficacy data for first drug candidate in RP11 due in Q2 2025
Clinical efficacy data for the first drug candidate to progress into human trials in Retinitis Pigmentosa 11 is due in Q2 20251 Program 2025 2026 2027 20282 RP11 Ph1/2 study Registrational study VP-001 NDA Monogenic blinding eye Product launch and transition disease of childhood 1 to commercial-stag
Slide 14: Principal Investigator comment on RP type 11 trial
“[My patient] now sees airplanes in the sky (never had before), stars at night, animals/creatures along the road … The stories go on” Principal Investigator in PYC’s RP type 11 phase 1/2 clinical trial Comments reflect patient reported outcomes following treatment with VP-001 in an open-label study
Slide 15: PYC will commence registrational studies in RP11 in 2025
PYC will commence registrational studies in RP11 in 20251 1H 2025 2H 2025 Timeline PYC’s RP11 program development stage Phase 1/2 Phase 3 Milestones1 • Safety and efficacy data for all patients • Commencement of a registrational trial enrolled in PYC’s ongoing Phase 1/2 • Continuation of the Phase 1
Slide 16: PYC has the option of developing or partnering each asset in its pipeline
PYC has the option of developing or partnering each asset in its pipeline Recent blinding eye disease licensing deals/acquisitions by stage of development compared to PYC’s RP11 program1 Timeline 2025 2026 2027 PYC’s progress PYC’s RP11 program Phase 1/2 Phase 3 development stage Illustrative compar
Slide 17: Urgent need to create treatment options for the PKD patient community
There is an urgent need to create treatment options for the Polycystic Kidney Disease (PKD) patient community Healthy adult kidney Polycystic kidney Polycystic Kidney Disease High prevalence PKD affects 1 in every 1,000 people meaning >5 million people worldwide have the disease1,2 Life-changing Hal
Slide 18: PYC has progressed a drug with disease-modifying potential into human trials in PKD
PYC has progressed a drug with disease-modifying potential into human trials in PKD Clinical pathway1,2 2025 2026 2027 2028 2029 Phase 2 Pivotal for Marketed Phase 1 SAD/MAD NDA Accelerated Approval drug Regulatory Established accelerated approval path approval for for PKD in the US allows for Phase
Slide 19: PYC in 2025
PYC in 2025 • Developing life-changing drugs for patients with major unmet medical needs • Generating human efficacy data for multiple drug candidates with potential to become the standard of care in markets worth $1-10 billion p.a.1 • Human safety and efficacy data in both blinding eye disease prog
Slide 20: Overview of the Offer
Life-changing science Overview of the Offer
Slide 21: Overview of the Offer
Overview of the Offer Offer • PYC is seeking to raise approximately A$145.8 million via the issue of approximately 117 million new fully paid ordinary shares (“New Shares”) • The Offer will consist of a 1 for 4 pro-rata accelerated non-renounceable entitlement offer (“ANREO”) (“Entitlement Offer”) (
Slide 22: Indicative timeline
Indicative timeline1 Event Timing (AWST) Trading halt Monday, 17 February 2025 Announcement of Entitlement Offer Monday, 17 February 2025 Institutional Entitlement Offer opens Monday, 17 February 2025 Institutional Entitlement Offer closes 4.00pm (AWST) Tuesday, 18 February 2025 Announcement of resu
Slide 23: Use of proceeds and Pro Forma Capital Structure – $146m raise
Use of proceeds and Pro Forma Capital Structure – $146m raise1 Sources of funds2 Amount Pro Forma Capital Structure Amount Cash on hand $49.3m Ordinary shares on issue prior to the Offer 466.6m Anticipated FY25 R&D rebate $20.0m Undiluted market capitalisation prior to the Offer4 $599.6m Capital rai
Slide 24: Appendix A: Key Risks
Life-changing science Appendix A: Key Risks
Slide 25: Appendix A: Key Risks
Appendix A: Key Risks Disclaimer This section discusses some of the key risks associated with any investment in PYC, which may affect the value of PYC shares. The risks set out below are not listed in order of importance and do not constitute an exhaustive list of all risks involved with an investme
Slide 26: Appendix A: Key Risks continued
Appendix A: Key Risks continued Research and development PYC can make no representations that any of its research and development will be successful, that PYC’s development milestones will be achieved or that PYC will develop products that are commercially exploitable. Prior to commercialisation, pr
Slide 27: Appendix A: Key Risks continued
Appendix A: Key Risks continued Competition The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change, both in Australia and internationally, and there are no guarantees about PYC’s ability to successfully compete. Although th
Slide 28: Appendix A: Key Risks continued
Appendix A: Key Risks continued PYC is dependent on key PYC depends on being able to attract and retain personnel with specialist expertise, and to ensure continuity of key management. The loss of one or more key personnel members of the management team could material affect PYC’s ability to pursue
Slide 29: Appendix A: Key Risks continued
Appendix A: Key Risks continued Regulatory Approval PYC operates within a highly regulated industry, relating to the manufacture, distribution and supply of pharmaceutical products. Accordingly, PYC is continually exposed to the risk of changes in laws, regulation and government policies in Australi
Slide 30: Appendix A: Key Risks continued
Appendix A: Key Risks continued Cyber security PYC relies heavily on its information technology systems including its networks, equipment, hardware, software, telecommunications and other information technology (collectively, IT Systems), and the IT Systems of third-party service providers, to opera
Slide 31: Appendix A: Key Risks continued
Appendix A: Key Risks continued Dilution risk Existing shareholders who do not participate in the Offer will be diluted as a result of the issue of new shares. A participating shareholder may still be diluted even though they participate in the Offer, depending on the number of shares issued to them
Slide 32: Appendix B: International Offer Restrictions
Life-changing science Appendix B: International Offer Restrictions
Slide 33: Appendix B: International Offer Restrictions
Appendix B: International Offer Restrictions International Offer Restrictions This document does not constitute an offer of new ordinary shares (“New Shares”) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the
Slide 34: Appendix B: International Offer Restrictions (continued)
Appendix B: International Offer Restrictions International Offer Restrictions (continued) This document has been given to you on the basis that you are an “institutional investor” or an “accredited investor” (as such terms are defined in the SFA). If you are not such an investor, please return this
Slide 35: Appendix C: Summary of Retail Offer underwriting terms
Life-changing science Appendix C: Summary of Retail Offer underwriting terms
Slide 36: Appendix C: Summary of underwriting terms for the Retail Offer
Appendix C: Summary of underwriting terms for the Retail Offer Key terms of the Underwriting Agreement to the Retail Offer The Company has entered into an underwriting agreement with five (5) separate investors from its longstanding top 40 shareholders (Underwriting Agreement). The material terms ar
PYC Therapeutics — Investor Presentation (February 2025) on 6ix